LGC to develop new Berlin site to expand nucleic acid therapeutics capacity
New facility will allow for the delivery of integrated analytical and manufacturing solutions spanning early discovery to clinical development
18 Nov 2021
Industry news
LGC has announced a major new expansion, the development of a new site in Berlin for its LGC Axolabs Nucleic Acid Therapeutics (NAT) unit.
The site will be dedicated to medium to large scale and early to late Phase Clinical GMP manufacturing of nucleic acid therapeutics. The operational start date is scheduled for 2024.
Juergen Muller, Commercial and Strategic Development Director, LGC, said, “With this new facility LGC Axolabs expands the services for NAT from early discovery and lead development to clinical development and beyond – an unmatched and unique services portfolio. LGC is a world-leading solutions provider for NAT, with capabilities in GMP oligo manufacture, CMC analytical, and bioanalytical services. This state-of-the-art facility in Berlin will allow us to deliver integrated analytical and manufacturing solutions - spanning lead discovery through to the clinic and beyond – for all of our customers around the world.”
LGC Axolabs has expertise in a wide range of NAT modalities, including antisense oligos, siRNAs, immunostimulatory oligos, aptamers, miRNAs and miRNA antagonists, and guide RNAs for CRISPR applications. As part of the broad LGC group, LGC Axolabs Berlin’s backwards integration allows in-house access to solid supports and reagents/amidites dedicated to oligo production.
With this expansion, LGC’s offering is evolving into a late-stage clinical supply of NAT and will complement its other CMC teams in Kulmbach (Germany), Petaluma (USA), Sandwich (UK), and Fordham (UK).
Want the latest science news straight to your inbox? Become a SelectScience member for free today>>
Related products
Request Quote for All Products
oKtopure™ - Automated nucleic extraction platform
LGC Diagnostics and Genomics - Rapid Genomics Genotyping SolutionsThe oKtopure™ is a fully automated nucleic acid extraction instrument that enables a new level of high-throughput processing and significant cost savings. This platform combines standardised high-throughput DNA or RNA extraction from a variety of sample types with the proprietary sbeadex™ magentic bead based extraction chemistry. The oKtopure is part of our on-going programme to provide customers with high productivity solutions, first developed and optimised for use within our service labs, where every day we deliver Extraction, Sequencing and Genotyping services. Key to the delivery of consistently high quality and high yield DNA preparations from the oKtopure is its ability to bind and hold the magnetic beads, and hence the DNA in place whilst transferring the buffers required for washing, binding and elution steps. The final aqueous wash used in the sbeadex extraction protocols enables the delivery of nucleic preparations ideal for downstream applications such as SNP genotyping, NGS and Sanger sequencing. Features: High throughput - capable of processing eight 96-well plates (768 samples) in approximately one-and-a-half hours Robust tip washing system reduces consumable costs by 50% or more Preloaded methods for different sample types – fully customizable Extraction expertise and support from scientists who use the instrument daily and have been carrying out high throughput extractions since 1996!